source
- BioMarin signs new deal for early-stage bone disease assetBioMarin recently halted development of a rare disease drug that it had acquired in a $270 million transaction. Within a week, the company announced another deal to acquire an early‑stage asset aim…
- Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilarsThe initial batch of biosimilars includes copies of Amgen, Eli Lilly and GSK drugs that collectively generate billions of dollars in annual revenues.